 Gastrointestinal Agents
"Gastrointestinal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
| Descriptor ID |
D005765
|
| MeSH Number(s) |
D27.505.954.483
|
| Concept/Terms |
Gastrointestinal Agents- Gastrointestinal Agents
- Agents, Gastrointestinal
- Gastrointestinal Drugs
- Drugs, Gastrointestinal
Gastric Agents- Gastric Agents
- Agents, Gastric
- Gastric Drugs
- Drugs, Gastric
|
Below are MeSH descriptors whose meaning is more general than "Gastrointestinal Agents".
Below are MeSH descriptors whose meaning is more specific than "Gastrointestinal Agents".
This graph shows the total number of publications written about "Gastrointestinal Agents" by people in this website by year, and whether "Gastrointestinal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 2 | 3 | | 1999 | 3 | 0 | 3 | | 2000 | 3 | 1 | 4 | | 2001 | 4 | 0 | 4 | | 2002 | 6 | 2 | 8 | | 2003 | 3 | 0 | 3 | | 2004 | 4 | 2 | 6 | | 2005 | 6 | 1 | 7 | | 2006 | 3 | 3 | 6 | | 2007 | 6 | 3 | 9 | | 2008 | 1 | 0 | 1 | | 2009 | 2 | 2 | 4 | | 2010 | 2 | 0 | 2 | | 2011 | 7 | 0 | 7 | | 2012 | 2 | 0 | 2 | | 2013 | 2 | 0 | 2 | | 2014 | 5 | 0 | 5 | | 2015 | 3 | 2 | 5 | | 2016 | 9 | 0 | 9 | | 2017 | 6 | 0 | 6 | | 2018 | 11 | 3 | 14 | | 2019 | 5 | 0 | 5 | | 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Gastrointestinal Agents" by people in Profiles.
-
Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
-
Cohen RD, Bhayat F, Blake A, Travis S. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis. 2020 Feb 10; 14(2):192-204.
-
Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
-
Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
-
Dwadasi S, Israel A, Rubin DT. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
-
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
-
Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
-
Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
-
Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
-
Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 01; 17(1):139-147.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|